PLoS One – Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica

A new study by the International Agency for Research on Cancer (IARC), in partnership with Costa Rican investigators and the United States National Cancer Institute (NCI), shows for the first time that the vaccine against human papillomavirus (HPV) types 16 and 18, which is used to prevent cervical cancer, also provides strong protection against oral HPV infections, known to be associated with cancer of the oropharynx and tonsils.

R Herrero, W Quint, A Hildesheim, P Gonzalez, L Struijk, H A Katki et al.
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.
PLoS One (2013). http://dx.plos.org/10.1371/journal.pone.0068329

Read IARC Press Release 220
Leer IARC Nota de Prensa 220
Read article